

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

NOTICE OF POSTPONEMENT OF BOARD MEETING

The board (the “**Board**”) of directors (the “**Directors**”) refers to the announcement of Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) dated 18 June 2025 in relation to the sixth meeting of the second session of the Board (the “**Board Meeting**”) proposed to be held virtually at 11:00 a.m. on Friday, 27 June 2025 for the purposes of considering and approving, among other matters, (i) considering and, if thought fit, approving the consolidated annual results of the Company and its subsidiaries for the year ended 31 December 2024 (the “**Annual Results**”) and its publication; (ii) considering the payment of a final dividend, if any; and (iii) transacting any other business.

The Board wishes to announce that since additional time is required for the Company and its auditor to review and finalise the Annual Results, the date of the Board Meeting will be postponed from Friday, 27 June 2025 to Monday, 30 June 2025.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairperson and Executive Director

Beijing, the PRC, 27 June 2025

As at the date of this notice, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.